Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teleflex
TFX
|
+$52.1M |
| 2 |
Warner Bros
WBD
|
+$34M |
| 3 |
Viatris
VTRS
|
+$33.3M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$28.3M |
| 5 |
Akamai
AKAM
|
+$27.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Molson Coors Class B
TAP
|
+$37.4M |
| 2 |
Eversource Energy
ES
|
+$34.8M |
| 3 |
AT&T
T
|
+$30M |
| 4 |
SS&C Technologies
SSNC
|
+$28M |
| 5 |
Progyny
PGNY
|
+$27.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.24% |
| 2 | Consumer Discretionary | 18.14% |
| 3 | Healthcare | 12.54% |
| 4 | Industrials | 8.78% |
| 5 | Communication Services | 8.66% |
Similar funds
Invenomic Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, Invenomic Capital Management held 209 positions worth $1.98B, down 5.8% from $2.1B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Invenomic Capital Management deployed $122M of net new capital in Q1 2025, opening 50 new positions and adding to 69 existing holdings. Its largest new stake was Warner Bros: 3,254,123 shares worth $34.9M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Eversource Energy, an estimated $34.8M trimmed.
- Invenomic Capital Management's largest Q1 2025 buy was Warner Bros: 3,254,123 shares worth $34.9M.
- Invenomic Capital Management added most to Teleflex in Q1 2025, an estimated $52.1M increase.
- Invenomic Capital Management's biggest Q1 2025 reduction was Eversource Energy, cutting an estimated $34.8M.
- Invenomic Capital Management fully exited Molson Coors Class B in Q1 2025, selling an estimated $37.4M.
- Invenomic Capital Management's ten largest holdings make up 22% of its $1.98B portfolio in Q1 2025.
- Invenomic Capital Management opened 50 new positions and closed 37 in Q1 2025.
- Invenomic Capital Management's portfolio value fell 5.8% quarter-over-quarter to $1.98B.
Based on Invenomic Capital Management's 13F filing for Q1 2025, filed 15 May 2025.